[go: up one dir, main page]

WO2025176912A1 - Sachet pour administration transmucosale d'un composé actif - Google Patents

Sachet pour administration transmucosale d'un composé actif

Info

Publication number
WO2025176912A1
WO2025176912A1 PCT/EP2025/054918 EP2025054918W WO2025176912A1 WO 2025176912 A1 WO2025176912 A1 WO 2025176912A1 EP 2025054918 W EP2025054918 W EP 2025054918W WO 2025176912 A1 WO2025176912 A1 WO 2025176912A1
Authority
WO
WIPO (PCT)
Prior art keywords
matrix material
lozenges
compound
pouch
neuroactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/054918
Other languages
English (en)
Inventor
Nicholas Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
State Mode Medical Ltd
Original Assignee
State Mode Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by State Mode Medical Ltd filed Critical State Mode Medical Ltd
Publication of WO2025176912A1 publication Critical patent/WO2025176912A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • the term ‘psychoactive compound’ encompasses substances that can affect the brain and alter mental processes of a subject such as mood, perception, cognition, and behaviour. These substances act on the central nervous system and can induce changes in consciousness and thought patterns. Examples of psychoactive substances include drugs like LSD, psilocybin (found in magic mushrooms), MDMA, and THC (found in marijuana).
  • bioactive compound encompasses substances that have an effect on living organisms, encompassing both neurological and non-neurological effects.
  • Bioactive compounds may interact with various biomolecules and biological systems, impacting physiological processes beyond just the nervous system. These effects can include antioxidant properties, anti-inflammatory actions, hormonal regulation, and more.
  • Bioactive substances can be found in various natural sources like plants, animals, and microorganisms. Bioactive compounds may be found in Ganoderma Sichuanense (Reishi Mushroom) and Lion’s mane mushroom.
  • the neuroactive, psychoactive and bioactive compounds referred to herein are compounds that are capable of passing the blood-brain barrier. These compounds are therefore termed brain-penetrant compounds. Such compounds may also be termed Central Nervous System (CNS)-active or CNS-penetrant, meaning that they not only are capable of passing through the blood-brain barrier, but are also pharmacologically active in the CNS.
  • CNS Central Nervous System
  • the effect of brainpenetrant compounds is that they are able to be absorbed by the brain or wider CNS directly from blood vessels.
  • a pouch for controlling release of a neuroactive and/or psychoactive compound in the mouth of a human or animal subject comprising: a liquid permeable cover; and a plurality of dissolvable lozenges contained within the cover, each of the plurality of lozenges comprising: a matrix material forming a shape of the lozenge, said shape having a surface area, the matrix material being dissolvable in the mouth of the human or animal subject at a dissolution rate; and a neuroactive and/or psychoactive compound suspended within the matrix material at a compound concentration, wherein each lozenge has a known release rate of the neuroactive and/or psychoactive compound in the mouth of the user that is determined based on the surface area, the dissolution rate and the compound concentration and is sustained within upper and lower release rate limits over a release time period.
  • Such a pouch allows for precise control and maintenance of a release rate of the neuroactive and/or psychoactive compound over a sustained period of time. As the matrix material dissolves, the neuroactive and/or psychoactive compound is released from the lozenges at a controlled rate.
  • the combination of release rates of each lozenge can be selected to allow fine control over the overall release rate of the pouch. The invention therefore allows for a finely determined release rate of a neuroactive and/or psychoactive compound that can be within tolerances over a sustained period of time.
  • the first matrix material is different to the second matrix material; the first compound concentration is different to the second compound concentration; and/or the first surface area is different to the second surface area.
  • the first release rate is different to the second release rate.
  • a release rate of the pouch may be based on a combination of the first and second release rates and/or a permeability of the liquid permeable cover.
  • the overall release rate of the pouch is determined based, at least in part, on a combination of a plurality of neuroactive and/or psychoactive compounds in the first and/or second lozenges.
  • one or more of the plurality of lozenges includes an absorption enhancer for increasing a rate of absorption of the neuroactive and/or psychoactive compound by the human or animal subject.
  • the oral indicator is suspended within the matrix material of the at least one of the plurality of lozenges, and wherein the predetermined period of time is dependent on the dissolution rate of the matrix material and/or a surface area of the lozenge.
  • the oral indicator comprises a substance configured to change a flavour profile in the mouth of the human or animal subject.
  • the release time period is one of: in a range from 5 minutes to 3 hours; in a range from 5 minutes to 2 hours; in a range from 5 minutes to 1 hour; and in a range from 30 seconds to 30 minutes.
  • the pouch further comprises an inner pouch, the inner pouch comprising: an inner liquid permeable cover; and a plurality of further dissolvable lozenges contained within the inner cover
  • a liquid permeability of the permeable cover is different to a liquid permeability of the inner permeable cover.
  • the one or more lozenges of the plurality of lozenges comprises a plurality of layers, wherein an outer layer comprises an outer matrix material and an outer compound concentration, and wherein an inner layer comprises an inner matrix material and an inner compound concentration.
  • the inner layer is exposed upon at least partial dissolution of the outer layer.
  • a release rates of the neuroactive and/or psychoactive compound caused by the outer layer and the inner are within the upper and lower release rate limits.
  • the neuroactive and/or psychoactive compound comprises psilocybin or psilocyn.
  • a pouch for transmucosal delivery of a neuroactive, psychoactive and/or bioactive compound in the mouth of a human or animal subject comprises a liquid permeable cover; and a plurality of dissolvable lozenges contained within the cover.
  • Each of the plurality of lozenges comprises a matrix material; and a neuroactive, psychoactive and/or bioactive compound suspended within the matrix material.
  • a first lozenge of the plurality of lozenges comprises a first matrix material and a first concentration of a neuroactive, psychoactive and/or bioactive compound suspended in the first matrix for delivering a first dosage profile to the human or animal subject.
  • a second lozenge of the plurality of lozenges comprises a second matrix material and a second concentration of the and/or a further neuroactive, psychoactive and/or bioactive compound suspended in the second matrix for delivering a second dosage profile to the human or animal subject.
  • the first lozenge and second lozenge comprise the same neuroactive, psychoactive and/or bioactive compound.
  • the concentration of the or each neuroactive, psychoactive and/or bioactive compound suspended in each respective matrix material is the same.
  • the first and the second dosage profiles combine to determine an overall dosage profile for the pouch.
  • the first and/or the second dosage profiles result in an absorption rate and/or a release rate of the neuroactive, psychoactive and/or bioactive compound that remains within a range defined by an upper dosage profile threshold and a lower dosage profile threshold.
  • the first and/or second dosage profile is dependent on one or more of: a surface area of the first and/or second lozenge; a concentration of the first and/or the further neuroactive, psychoactive and/or bioactive compound suspended in the first and/or the second matrix; and a rate of dissolution of the first and/or second matrix.
  • the first concentration and/or the second concentration is substantially evenly distributed within the first and/or second matrix material.
  • the first concentration is less than the second concentration.
  • the first and/or second lozenges include an absorption inhibiter for reducing a rate of absorption of the neuroactive, psychoactive and/or bioactive compound by the human or animal subject.
  • the oral indicator comprises a substance configured to change a flavour profile in the mouth of the human or animal subject.
  • the first and/or second matrix materials include a sugar-based substance, a cellulose derivative substance and/or a polymer.
  • the pouch further comprises an inner pouch and the inner pouch comprises an inner liquid permeable cover; and a plurality of inner dissolvable lozenges contained within the inner cover.
  • Each of the plurality of inner lozenges comprises an inner matrix material; and the and/or a further neuroactive, psychoactive and/or bioactive compound suspended within the inner matrix material.
  • a first inner lozenge of the plurality of inner lozenges comprises a first inner matrix material and a first inner concentration of the and/or a further neuroactive, psychoactive and/or bioactive compound suspended in the first inner matrix; and a second inner lozenge of the plurality of inner lozenges comprises a second inner matrix material and a second inner concentration of the and/or a further neuroactive, psychoactive and/or bioactive compound suspended in the second inner matrix.
  • a liquid permeability of the permeable cover is different to a liquid permeability of the inner permeable cover.
  • the first lozenge of the plurality of lozenges comprises a plurality of layers, wherein a first layer of the plurality of layers comprises the first matrix material and the first concentration of the neuroactive, psychoactive and/or bioactive compound suspended in the first matrix for delivering the first dosage profile to the human or animal subject; and a second layer of the plurality of layers comprises a third matrix material and a third concentration of the and/or a further neuroactive, psychoactive and/or bioactive compound suspended in the third matrix for delivering a third dosage profile to the human or animal subject.
  • a difference between an absorption rate and/or a release rate of the neuroactive or bioactive compound in the first and second dosage profiles is less than a dosage threshold value.
  • the neuroactive, psychoactive and/or bioactive compound comprises psilocybin or psilocyn.
  • Figure 1 is an example of a typical dosage profile for an active compound that is ingested orally by a user
  • Figure 2 is a section through an example pouch for transmucosal delivery of an active compound
  • Figure 3 is an example of a pouch that comprises an outer liquid permeable cover and an inner liquid permeable cover;
  • Figure 4 is an example of a section through a lozenge for inclusion in a pouch.
  • Figure 1 shows a typical dosage profile 100 that can be seen using these methods of delivery.
  • the y-axis of Figure 1 shows absorption of the active compound, and the x-axis shows time. Because the active compound is delivered in a single dose, levels of compound absorption grow to a peak and then reduce over time, as shown in the typical dosage profile 100.
  • the optimal dosage profile 108 increases active compound absorption until it reaches the optimal region 106, where it flattens off to maintain the correct level of active compound absorption over time. Active compound absorption may remain within predetermined compound absorption limits, such as the limits of the optimal region 106.
  • the optimal region 106 is in a range from an upper dosage profile threshold 110 to a lower dosage profile threshold 112. Figure 1 shows the optimal dosage profile 108 as being flat after reaching the optimal region 106. However, it will be appreciated that the optimal dosage profile 108 may exhibit increased or decreased active compound absorption over time, whilst staying within the optimal region 106.
  • the term ‘dosage profile’ as used herein encompasses a rate of active compound absorption by a subject.
  • the active compound absorption and rate of active compound release may be proportional but not necessarily equal. Differences in active compound absorption and rate of active compound release may be based on factors that are specific to a human or animal subject. Accordingly, the optimal region 106 of Figure 1 may be expressed as a region having a rate of active compound absorption, or rate of release of the active compound from the lozenge as it dissolves, that lies between upper and lower thresholds 110, 112. Methods and apparatus disclosed herein are related to controlling a rate of release of an active compound.
  • lozenge may encompass any type or shape of tablet configured to dissolve in the mouth of a subject at a known rate. Accordingly, the lozenge may be hard or brittle, gum like structure or have any other structure capable of holding its own weight. The lozenge is formed by the matrix material and is configured to be held in the mouth of a user and dissolved over time to release the active compound held therein.
  • a first lozenge 204 includes a first matrix material and has a first compound concentration of at least one active compound suspended within the first matrix.
  • the first matrix material forms the outer shape of the first lozenge 204, giving the first lozenge a first surface area.
  • the first lozenge 204 is configured to release the active compound(s) at a first release rate, which is defined by a combination of the dissolution rate of the first matrix material, the first compound concentration and the first surface area.
  • the first release rate may proportional to a first dosage profile associated with the first lozenge 204.
  • the first release rate is different to the second release rate.
  • the pouch 200 includes a plurality of lozenges two or more of which may have different release rates, although it is noted that some of the plurality of lozenges may have the same release rate.
  • the release rate of a lozenges may be dependent on one or more of: a rate of dissolution of the matrix material; a concentration of the at least one active compound; and a surface area of the lozenge that is exposed in the mouth of the human or animal subject (this may be proportional to the size of the lozenge).
  • a lozenge may be configured using the features identified in the paragraph above to have a specific release rate profile. If the surface area of a lozenge is increased then the rate of release of the active compound is increased, and vice-versa. If the rate of dissolution of the matrix material is increased then the rate of release of the active compound is increased, and vice-versa. If the concentration of the active compound suspended in the matrix material is increased then the rate of release of the active compound is increased, and vice-versa.
  • the liquid permeable cover 202 is configured to allow saliva to pass through for dissolution of the lozenges 204, 206, 208.
  • the permeability of the liquid permeable cover 202 may determine the overall compound release rate of the pouch 200. A more permeable cover will increase the release rate of the pouch and vice-versa.
  • One or more of the lozenges 204, 206, 208 may be configured to give an oral indication to the human or animal subject after a period of time.
  • An oral indication encompasses any indication that may be detected by the subject through the mouth.
  • the oral indication may include a flavour that is detectable by the subject, or a chemical reaction in the mouth of the subject.
  • one or more lozenges 204, 206, 208 may include a flavoured compound suspended in a matrix material thereof.
  • the flavoured compound may be suspended in the matrix material below a surface of the lozenge 204, 206, 208 such that an outer layer of the lozenge 204, 206, 208 must be dissolved before the flavoured compound is released into the mouth of the subject.
  • the time taken to dissolve the outer layer of the lozenge 204, 206, 208 is dependent on a rate of dissolution of the matrix material of the outer layer and/or a surface area of the outer layer.
  • the flavoured compound may be replaced with an alternative compound giving an alternative oral indication to the subject.
  • the oral indication may be timed to coincide with a particular point in the overall dosage profile (or active compound release) of the pouch 200.
  • the oral indication may prompt the subject to remove the pouch 200 from their mouth when a required amount of the active compound has been released or a required dosage has been reached.
  • the oral indication may illicit an involuntary action in the subject, such as a foul taste that causes the subject to instantly and rapidly remove the pouch 200 from the mouth.
  • the release rate of the active compound from the pouch 200 is based on (and may be proportional to) the combined release rates of the plurality of lozenges 204, 206, 208 in the pouch. This gives fine control over the release rate of the pouch 200 over time.
  • a desired release rate of the pouch may be achieved by combining, within the pouch a plurality of lozenges 204. 206, 208 that each has a known release rate.
  • the controlled release of the lozenges 204, 206, 208 means that the pouch release rate will remain within upper and lower release rate limits over a period of time.
  • the period of time may be the length of time that it takes for one or more of the lozenges to dissolve, or for a layer of one or more of the lozenges to dissolve.
  • the period of time may be in a range from in a range from 5 minutes to 3 hours; in a range from 5 minutes to 2 hours; in a range from 5 minutes to 1 hour; and in a range from 30 seconds to 30 minutes. Release of the total active compound suspended in the matrix material is not instant, but is controlled over time.
  • Figure 3 shows an exemplary pouch 300 including an outer liquid permeable cover 302 and an inner liquid permeable cover 304.
  • the outer liquid permeable cover includes a plurality of outer lozenges 306.
  • the inner liquid permeable cover 304 is at least partially contained within the outer liquid permeable cover 302.
  • the inner liquid permeable cover 304 includes one or more inner lozenges 308.
  • the outer liquid permeable cover 302 and the inner liquid permeable cover 304 may have different permeabilities.
  • the inner liquid permeable cover 304 may have a greater permeability than the outer liquid permeable cover 302.
  • the inner liquid permeable cover 304 may have a lower permeability than the outer liquid permeable cover 302.
  • the relative permeability of the inner and outer liquid permeable covers 302, 304 may allow greater control over the release rate of the active compound and the overall release rate profile of the pouch 300.
  • the release rate of the inner lozenges 308 may be restricted or enhanced by greater or lesser permeability of the inner liquid permeable cover 304.
  • Figure 4 shows a section through a lozenge 400 for inclusion in pouch 200, 300.
  • the lozenge 400 has a circular section and may be spherical or disc shaped. It will be appreciated that any other shapes of lozenge are possible and are encompassed by this disclosure, e.g., a rhomboid, a capsule shape or a pill shape.
  • the exemplary lozenge 400 includes a plurality of layers and, in the case of Figure 4, a first layer 402 and a second layer 404. It will be apparent to a skilled person that further layers may be included, if desired or that there may be a single layer.
  • the plurality of layers 402, 404 may be concentric and share a common centre.
  • the first layer 402 may encompass the second layer 404. Where further layers are included, these may also be concentric and be encompassed by one or more outer layers.
  • the first layer 402 may be adjacent to the second layer 404.
  • a spacer layer containing no active compound may be placed between the first and second layers 402, 404.
  • the spacer layer may be dissolvable and may comprise the matrix material.
  • the active compound may be any neuroactive, psychoactive or bioactive substance or compound, e.g., psilocybin or psilocylin.
  • the active compound may be evenly distributed within the first and/or second layers 402, 404.
  • the concentration of the active compound within the first and/or second layers 402, 404 may be isotropic.
  • the fist layer 402 comprises a outer matrix material and an outer concentration of the active compound suspended in the outer matrix material.
  • the outer matrix material and the outer concentration of the active compound are configured to achieve an outer release rate profile for the active compound.
  • the inner layer 404 may comprise an inner matrix material and an inner concentration of the active compound suspended in the inner matrix material.
  • the inner matrix material and the inner concentration of the active compound are configured to achieve an inner release rate profile for the active compound.
  • the concentration of the active compound in the outer layer 402 may be less than the concentration of the active compound in the inner layer 404.
  • the concentration of the active compound in the outer layer 402 may be less than the concentration of the active compound in the inner layer 404.
  • the concentration of the active compound in the outer and inner layers 402, 404 and/or the rate of dissolution of the matrix material in the outer and inner layers 402, 404 determines the rate of release of the active compound and therefore the release rate profile of the lozenge 400 as it dissolves.
  • the concentration of the active compound in each layer and/or the rate of dissolution of the matrix material in each layer may be chosen based on layer thickness.
  • a plurality of active compounds may be included in the outer layer and suspended within the matrix material.
  • the ratio between the plurality of active compounds may affect the release rate profile. For example, if the outer layer includes a combination of psilocybin and psilocyn then the rate of absorption by the subject will be affected. Psilocyn is more quickly absorbed by the subject and so a higher ratio of psilocyn compared to psilocybin will increase the rate of absorption.
  • the matrix material in the inner layer 404 and/or outer layer 402 may comprise (or consist of) Isomalt.
  • a concentration of active compound suspended in the matrix material may be in a range from 5mg-15mg of active compound per 5mg-10mg of matrix material. In a specific example, the concentration may be approximately 10mg of active compound per 5mg-10mg of matrix material. It will be appreciated that the concentration will depend on the user, the active compound(s) used and the desired outcomes for the user.
  • the lozenge 400 may include an outer protective coating of Shellac or Carnauba Wax.
  • One or more of the plurality of lozenges in a pouch may be spherical and have a diameter in a range from 0.5mm to 4mm, or in a range from 1mm to 4mm.
  • One or more of the plurality of lozenges in a pouch may have shapes other than spheres.
  • a volume of one or more of the lozenges may be in a range from 0.06 mm 3 to 34mm 3 .
  • a surface area of one or more of the plurality of lozenges in a pouch may be in a range from 0.75mm 2 to 55mm 2 .
  • One or more of the plurality of lozenges in a pouch may comprise an outer coating.
  • the outer coating may be dissolvable in the mouth of the subject.
  • a thickness of the outer layer may be configured to time a release of the active compound contained in the matrix material. Accordingly, a first lozenge may have an outer coating having a first thickness, and a second lozenge may have an outer coating of a second thickness that is greater than the first thickness. The first thickness may be zero in that the first lozenge may have no outer coating.
  • the optimal region may be different for different subjects as each subject may react to the active compound differently. Accordingly, it is envisaged that a number of lozenges may be available, wherein the dissolution rate and/or the active compound concentration in each layer of each lozenge is configured to provide a dosage profile that remains within different dosage threshold boundaries.
  • a plurality of lozenges may be manufactured, each having one of a plurality of predetermined release rate profiles.
  • a pouch may be manufactured by selecting two or more of the plurality of lozenges such that their release rate profiles combine to create a desired overall dosage profile.
  • the overall dosage profile may be determined based on physiological characteristics of a human or animal subject to whom the active compound is to be delivered.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un sachet pour réguler la libération d'un composé neuroactif et/ou psychoactif dans la bouche d'un sujet humain ou animal, le sachet comprenant un couvercle perméable aux liquides ; et une pluralité de pastilles solubles contenues dans le couvercle, chaque pastille de la pluralité de pastilles comprenant : un matériau de matrice formant une forme de pastille, ladite forme présentant une surface, le matériau de matrice pouvant se dissoudre dans la bouche du sujet humain ou animal à une vitesse de dissolution donnée ; et un composé neuroactif et/ou psychoactif en suspension à l'intérieur du matériau de matrice à une concentration de composé donnée, chaque pastille ayant un taux de libération connue du composé neuroactif et/ou psychoactif dans la bouche de l'utilisateur déterminée sur la base de la surface, du taux de dissolution et de la concentration du composé, et se maintenant dans les limites de taux de libération supérieure et inférieure sur une période de libération donnée.
PCT/EP2025/054918 2024-02-23 2025-02-24 Sachet pour administration transmucosale d'un composé actif Pending WO2025176912A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2402603.1A GB2638465A (en) 2024-02-23 2024-02-23 A pouch for transmucosal delivery of an active compound
GB2402603.1 2024-02-23

Publications (1)

Publication Number Publication Date
WO2025176912A1 true WO2025176912A1 (fr) 2025-08-28

Family

ID=90572523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/054918 Pending WO2025176912A1 (fr) 2024-02-23 2025-02-24 Sachet pour administration transmucosale d'un composé actif

Country Status (2)

Country Link
GB (1) GB2638465A (fr)
WO (1) WO2025176912A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210206554A1 (en) * 2019-12-09 2021-07-08 Nicoventures Trading Limited Oral product with dissolvable component
US20220331344A1 (en) * 2021-04-15 2022-10-20 Resurgent Biosciences, Inc Oral formulations of psychotropic macrofungus botanical extracts with mouthfeel experience enhancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7810507B2 (en) * 2006-02-10 2010-10-12 R. J. Reynolds Tobacco Company Smokeless tobacco composition
US20220225660A1 (en) * 2019-12-09 2022-07-21 Nicoventures Trading Limited Pouched products with heat sealable binder
PL4018848T3 (pl) * 2020-12-22 2024-11-25 Swedish Match North Europe Ab Wyrób w saszetkach do użytku doustnego zawierający materiał pokrywający przepuszczalny dla cieczy oraz materiał wypełniający

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210206554A1 (en) * 2019-12-09 2021-07-08 Nicoventures Trading Limited Oral product with dissolvable component
US20220331344A1 (en) * 2021-04-15 2022-10-20 Resurgent Biosciences, Inc Oral formulations of psychotropic macrofungus botanical extracts with mouthfeel experience enhancers

Also Published As

Publication number Publication date
GB2638465A (en) 2025-08-27
GB202402603D0 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
EP0490891B1 (fr) Matrice contenant un medicament
US12011504B2 (en) Blend compositions for oral administration as a rapidly dissolving powder and/or suspension
US4885173A (en) Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US6893654B2 (en) Two-stage transmucosal medicine delivery system for symptom relief
US20100104620A1 (en) Over-coated product including tableted center and medicament
ES2908977T3 (es) Forma de dosificación farmacéutica sólida para liberar en la cavidad oral al menos dos ingredientes farmacéuticos activos
MX2011003984A (es) Forma de dosis intraoral de multiples porciones y uso de esta.
ZA201002188B (en) Multi-portion intra-oral dosage form with organoleptic properties
US11185526B2 (en) Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
Rathod et al. Medicated lozenges as an easy to use dosage form
Jain et al. A review-formulation & development of orodispersible tablet
US20090202597A1 (en) Ache-Nmda Combination Wafer
WO2022221554A2 (fr) Compositions et procédés pour l'administration de psilocine et de promédicaments de celle-ci
WO2025176912A1 (fr) Sachet pour administration transmucosale d'un composé actif
GB2632261A (en) Transmucosal deliver of a drug
Pedersen Treatment of nocturnal asthma in children with a single dose of sustained‐release theophylline taken after supper
EP1387672A1 (fr) Produit aromatise contenant un medicament ou un autre agent actif
WO1994015595A1 (fr) Preparation comprenant une substance active pharmacologique/biologique
WO2018117855A1 (fr) Pastille effervescente
RU2426529C2 (ru) Орально распадающийся порошок, содержащий цилостазол и маннит
AU641127B2 (en) Compressed powder medicaments
Butkevych et al. Development of the composition and technology of an orodispersible film with melatonin and magnesium citrate
Kauser et al. Formulation and in vitro evaluation of anti-diabetic bi-layered tablet-Metformin and Ezetimibe
Patel et al. SUBLINGUAL ROUTE FOR SYSTEMIC DRUG DELIVERY
WO2021078999A1 (fr) Composition de gomme à mâcher ou de pastille comprenant du cbd

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25708139

Country of ref document: EP

Kind code of ref document: A1